ArticlePLoS pathogens2021
Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures.
Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Identification and validation of an autophagy-related signature for predicting survival in lower-grade glioma.Bioengineered · 2021Trial
- Nanostrategies synergize with locoregional interventional therapies for boosting antitumor immunity.Bioactive materials · 2025Article
- Evolution of Zika virus inVirus evolution · 2025Article
- Novel recombinant vaccinia virus-vectored vaccine affords complete protection against homologousEmerging microbes & infections · 2024Article
- Generating prophylactic immunity against arboviruses in vertebrates and invertebrates.Nature reviews. Immunology · 2024Review
- Microplastics dysregulate innate immunity in the SARS-CoV-2 infected lung.Frontiers in immunology · 2024Article
- EDIII-Fc induces protective immune responses against the Zika virus in mice and rhesus macaque.PLoS neglected tropical diseases · 2023Article
- Coding-Complete Genome Sequences of Copenhagen and Copenhagen-Derived vP811 Strains of Vaccinia Virus Isolated from Cell Culture.Microbiology resource announcements · 2023Article
- Emergence of SARS-CoV-2 spike protein at the vaccination site.Immunity, inflammation and disease · 2023Article
- Poxviruses and the immune system: Implications for monkeypox virus.International immunopharmacology · 2022Review
- Current Advances in Zika Vaccine Development.Vaccines · 2022Review
- The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.Immunology and cell biology · 2022Article
- Widespread discrepancy ineLife · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poxvirus systems have been extensively used as vaccine vectors. Herein a RNA-Seq analysis of intramuscular injection sites provided detailed insights into host innate immune responses, as well as expression of vector and recombinant immunogen genes, after vaccination with a new multiplication defective, vaccinia-based vector, Sementis Copenhagen Vector. Chikungunya and Zika virus immunogen mRNA and protein expression was associated with necrosing skeletal muscle cells surrounded by mixed cellular infiltrates. The multiple adjuvant signatures at 12 hours post-vaccination were dominated by TLR3, 4 and 9, STING, MAVS, PKR and the inflammasome. Th1 cytokine signatures were dominated by IFNγ, TNF and IL1β, and chemokine signatures by CCL5 and CXCL12. Multiple signatures associated with dendritic cell stimulation were evident. By day seven, vaccine transcripts were absent, and cell death, neutrophil, macrophage and inflammation annotations had abated. No compelling arthritis signatures were identified. Such injection site vaccinology approaches should inform refinements in poxvirus-based vector design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.